Prostate-Specific Antigen Test Market Size & Share 2026-2035

Prostate-Specific Antigen Test Market Size

The global prostate-specific antigen test market was valued at USD 5.1 billion in 2025. The market is expected to reach from USD 5.5 billion in 2026 to USD 10.1 billion in 2035, growing at a CAGR of 7.1% during the forecast period, according to the latest report published by Global Market Insights Inc.


The high market growth is attributed to the rising prevalence of prostate cancer, technological advancements in PSA testing, and expansion of diagnostic laboratory infrastructure, among other contributing factors.

The prostate-specific antigen test is a blood test that measures PSA, a protein generated by the prostate gland. It is typically used to detect prostate cancer, assess disease progression, and track treatment response, while elevated PSA levels may also suggest benign prostatic problems.

The major players in the global prostate-specific antigen test market are Abbott, Beckman Coulter, BIOMÉRIEUX, Roche, and SIEMENS Healthineers. These companies maintain their competitive position through ongoing product innovation, global market presence, and substantial investment in research and development.

The market has increased from USD 3.9 billion in 2022 and reached to USD 4.7 billion in 2024, with a historic growth rate of 10.1%. Higher screening uptake, increased routine health check-ups, improved test accessibility, favorable reimbursement in key markets, and growing awareness among at-risk populations all contributed to market growth.

Moreover, prostate cancer remains one of the most commonly diagnosed cancers among men globally, particularly in ageing populations. For instance, according to the World Health Organization (WHO), prostate cancer accounted for approximately 1.4 million new cases worldwide in 2022. Rising incidence rates across North America, Europe, and parts of Asia are driving increased demand for early diagnostic and screening tools. PSA testing continues to serve as a frontline method for initial detection and disease monitoring.

In addition, advances such as high-sensitivity assays, automated immunoassay platforms, and improved test accuracy have increased clinical confidence in PSA testing. Innovations such as PSA density, PSA velocity, and reflex testing improve diagnostic precision, allowing for greater clinical adoption.

Prostate-Specific Antigen Test Market Trends

The prostate-specific antigen test industry is growing considerably with the shift toward risk-adapted and selective PSA screening, growing use of PSA as a monitoring and surveillance tool, and integration of PSA testing with advanced diagnostic pathways, among other factors collectively driving industry growth.

• Clinical practice is shifting from blanket population screening to risk-based PSA testing. Age, family history, ethnicity, baseline PSA levels, and comorbidities are increasingly being used to inform testing decisions. This technique seeks to strike a compromise between early cancer detection and the risk of overdiagnosis. As a result, PSA testing has become more targeted and therapeutically relevant.
  
• Laboratories are shifting toward high-sensitivity PSA assays that enable detection at very low PSA levels, especially for post-treatment monitoring. Automation of immunoassay platforms improves throughput, reproducibility, and turnaround time. This trend supports large-scale screening programs and high-volume diagnostic laboratories, particularly in developed healthcare systems.
  
• Further, emerging economies are witnessing increased PSA test adoption due to expanding diagnostic infrastructure and rising cancer awareness. Private diagnostic chains and hospital networks are investing in immunoassay analyzers and standardized testing protocols. Growing middle-class populations and improving healthcare access are accelerating market penetration in Asia-Pacific, Latin America, and parts of the Middle East, thereby sustaining market growth.
  

Prostate-Specific Antigen Test Market Analysis

Based on product, the market is segmented into preliminary tests and confirmatory tests. The preliminary tests segment has asserted its dominance in the market by securing a significant market share of 68% in 2025 owing to the widespread use of PSA testing as a first-line screening tool, high testing volumes in routine health check-ups, and its cost-effectiveness and accessibility compared to confirmatory diagnostic procedures. The segment is expected to exceed USD 6.7 billion by 2035, growing at a CAGR of 6.8% during the forecast period.

• Preliminary tests, including total PSA, free PSA ratio, and initial screening panels, are used to determine prostate cancer risk before proposing biopsies. Clinicians choose non-invasive, low-cost preliminary tests for stratifying patients. This avoids unneeded intrusive treatments and promotes safer clinical decision-making.
  
• Healthcare systems face challenges in balancing cost-effective diagnostics with clinical accuracy. Preliminary PSA testing serve as a first-line filter, reducing the amount of costly imaging studies and biopsies. This cost-cutting method encourages widespread adoption in both public and private healthcare settings.
  
• The confirmatory tests segment held a revenue of USD 1.6 billion in 2025, with projections indicating a steady expansion at a CAGR of 7.5% from 2026 to 2035. The segment is motivated by the need to validate initial screening results, improve diagnostic accuracy, and reduce false positives while ensuring appropriate clinical decision-making. They are also fuelled by the increasing use of advanced multi-marker and molecular assays to supplement PSA testing for precise disease staging and monitoring.
  

Based on application, the prostate-specific antigen test market is classified into prostate cancer screening and prostate cancer monitoring. The prostate cancer screening segment dominated the market with a revenue share of 53.5% in 2025 and is expected to reach USD 5.1 billion within the forecast period.

• Prostate cancer is still a common cancer among males, especially in ageing populations in North America, Europe, and Asia. The increasing incidence is motivating proactive screening measures. PSA testing is a main technique for early detection, which has led to its widespread use in screening programs.
  
• Many countries conduct population-based or targeted screening programs for high-risk populations. PSA testing is commonly recommended as an early detection method in such projects. Institutional assistance reduces financial and logistical barriers for patients, resulting in increased test adoption.
  
• The prostate cancer monitoring segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 7.6% over the forecast period. The segment is being driven by the growing use of PSA assays to monitor treatment efficacy, detect recurrence early, and guide therapeutic adjustments, resulting in personalized patient management. Furthermore, the growing adoption of long-term follow-up protocols and their integration with digital health records promotes consistent monitoring and better clinical outcomes.
  

Based on end use, the prostate-specific antigen test market is classified into hospitals, diagnostic centers, specialty clinics, and other end users. The hospitals segment dominated the market with a revenue share of 39.1% in 2025 and is expected to reach USD 3.9 billion within the forecast period.

• Hospitals are the primary settings for PSA testing due to their high patient volume, which includes routine check-ups and symptomatic cases. High patient throughput ensures consistent test volume and revenue production. Hospitals frequently serve as referral centers for PSA testing, both confirmatory and follow-up.
  
• Hospitals offer urology, oncology, and preventive health services under one roof, allowing for seamless PSA testing and follow-up care. This integration enables coordinated disease management, from screening to diagnosis and treatment planning. It also builds clinical trust in PSA test results.
  
• The diagnostic centers segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 7.2% over the forecast period. The segment's growth is being fuelled by a focus on targeted urology care, personalized patient management, and the ability to provide comprehensive prostate health services. Furthermore, patient’s increasing preference for expert consultations and streamlined diagnostic workflows is driving PSA test adoption in these settings.
  
• The specialty clinics segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 7.6% over the forecast period. The segment's growth is being driven by their expertise in prostate care, personalized treatment approaches, and convenient access to advanced PSA testing, which attracts patients looking for specialized diagnostics.
  

North America Prostate-Specific Antigen Test Market

North America dominated the global prostate-specific antigen test industry with the highest share of 36.9% in 2025.

• The U.S. market was valued at USD 1.4 billion and USD 1.5 billion in 2022 and 2023, respectively. The market size reached USD 1.7 billion in 2025, growing from USD 1.6 billion in 2024, and is anticipated to grow at a CAGR of 6% from 2026 to 2035.
• North America has one of the highest incidences of prostate cancer globally, particularly in the U.S. The ageing male population, combined with widespread awareness of early detection, has led to a significant demand for PSA testing. Hospitals, diagnostic centers, and specialty clinics routinely adopt PSA tests as part of standard prostate cancer screening programs, driving consistent market growth.
  
• Furthermore, the region's sophisticated healthcare systems, which include cutting-edge laboratories and point-of-care testing facilities, facilitate the rapid adoption of PSA testing. High investment in healthcare technology ensures that advanced and next-generation PSA assays are widely available, thereby increasing market penetration.
  

Europe Prostate-Specific Antigen Test Market

Europe market accounted for USD 1.5 billion in 2025 and is anticipated to show lucrative growth over the forecast period.

• European countries, particularly Western Europe, have well-defined clinical guidelines that recommend PSA screening for men over 50 or at high risk. Compliance with these protocols drives up demand for PSA tests in hospitals, diagnostic labs, and outpatient clinics.
• Strong public healthcare systems and government-sponsored health programs ensure widespread access to PSA testing. Awareness campaigns and patient education initiatives encourage men to have regular screenings, which drives volume growth.
  
• Furthermore, private and public stakeholders are increasing their investments in preventive diagnostics. Health check-up packages, occupational health programs, and insurance coverage for routine screenings all contribute to the demand for PSA testing.
  

Asia Pacific Prostate-Specific Antigen Test Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 8.5% during the analysis timeframe.

• Prostate cancer prevalence is rising in countries like Japan, China, South Korea, and India due to ageing populations and lifestyle changes. The need for early diagnosis and monitoring is fuelling PSA test adoption in hospitals and specialized clinics.
  
• Advanced automated immunoassays and emerging multi-marker platforms are being gradually introduced in leading APAC markets, improving test accuracy and attracting adoption in both hospitals and specialty urology clinics.
  

Latin America Prostate-Specific Antigen Test Market

The Latin America market is experiencing robust growth over the analysis timeframe.

• Growing awareness among men in Brazil, Argentina, and Mexico about prostate cancer risks and early detection is encouraging PSA screening. Educational campaigns and physician recommendations drive adoption in urban healthcare facilities.
  
• Rising income levels in urban centers improve affordability for preventive health services, including PSA testing. Patients are more willing to undergo routine screenings, boosting demand in both hospital and clinic settings.
  

Middle East & Africa Prostate-Specific Antigen Test Market

The Middle East & Africa (MEA) market is experiencing robust growth over the analysis timeframe.

• Governments in GCC countries and parts of Africa are investing in hospital expansion, laboratory modernization, and advanced diagnostic equipment, facilitating access to PSA testing for a larger patient base.
  
• Hospitals and clinics in the MEA region are increasingly aligning with EAU and NCCN prostate cancer screening guidelines, supporting consistent adoption of PSA testing for early detection and monitoring.
  
• Further, private diagnostic centers and specialty clinics are growing in major urban centers, offering advanced PSA assays and personalized health packages, enhancing accessibility and market growth.
  

Prostate-Specific Antigen Test Market Share

The global prostate-specific antigen test industry  is competitive, dominated by a mix of global diagnostic leaders and specialized biotechnology firms. Market players focus on expanding their product portfolios through technological innovations, including next-generation immunoassays, multi-marker platforms, and point-of-care testing solutions.

Key players include Abbott, Beckman Coulter, BIOMÉRIEUX, Roche, and SIEMENS Healthineers, collectively accounting for ~74% of the total market share. These companies leverage strong distribution networks, robust R&D capabilities, and established relationships with hospitals, diagnostic centers, and specialty clinics to maintain leadership positions.

Competition is further intensified by the emergence of regional players and start-ups offering niche or cost-effective PSA testing solutions. Strategic initiatives such as mergers and acquisitions, collaborations, and partnerships are common as companies aim to broaden market reach and enhance technological capabilities.

Additionally, companies are increasingly focusing on expanding into emerging markets in Asia Pacific, Latin America, and the Middle East & Africa, where rising awareness and healthcare infrastructure investments offer new growth opportunities. The competitive landscape underscores a balance between innovation, accessibility, and strategic expansion to capture increasing global demand.

Prostate-Specific Antigen Test Market Companies

A few of the prominent players operating in the prostate-specific antigen test industry include:

• Abbott

• AdvaCare Pharma
• Beckman Coulter
• BIOMÉRIEUX
• CTK Biotech
• DiaSorin
• Fujirebio
• Intec
• KOELIS
• Labcorp
• mdxhealth
• Myriad Genetics
• OPKO Health
• Roche
• SIEMENS Healthineers
  
• Abbott

Abbott offers a comprehensive PSA testing portfolio with high accuracy and reliability, spanning both centralized laboratories and point-of-care platforms. Its strong global distribution network ensures widespread accessibility across hospitals and diagnostic centers.

• Roche

Roche leverages advanced automated immunoassay systems with clinically validated PSA tests, providing high sensitivity and consistency. Integration with digital health analytics enhances diagnostic decision-making and patient monitoring.

• SIEMENS Healthineers

SIEMENS Healthineers focuses on cutting-edge laboratory diagnostics and multi-marker platforms, improving PSA test precision and throughput. Its strong presence in hospital networks and specialty clinics supports rapid adoption and clinical trust.

Prostate-Specific Antigen Test Industry News:

• In March 2025, Onconetix, Inc. announced that new clinical data for Proclarix demonstrated improved diagnostic accuracy by reducing over-detection of clinically insignificant prostate cancer and unnecessary biopsies. The results validated its clinical utility in improving risk stratification among patients with elevated PSA levels. This advancement supports the PSA test market by enhancing test specificity, addressing key limitations, and strengthening clinician confidence in prostate cancer diagnostics.
  
• In January 2025, Biomerica, Inc. announced that its Fortel Prostate Specific Antigen (PSA) Screening Test had received approval from the UAE Ministry of Health and Prevention (MOHAP), enabling its use in the regional market. The test provided accurate results within 10 minutes using a simple finger-prick blood sample, supporting rapid and convenient screening. This development strengthened the market by expanding point-of-care testing adoption and improving accessibility to early prostate cancer detection.
  
• In September 2023, Oxford BioDynamics announced that it had validated its EpiSwitch Prostate Screening (PSE) blood test in its U.S. clinical laboratory, enabling immediate access for men at risk of prostate cancer. The validation demonstrated high diagnostic accuracy, supporting improved risk assessment alongside traditional PSA testing. This development strengthens the market by expanding advanced screening options and enhancing confidence in early prostate cancer detection.
  

The prostate-specific antigen test market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Preliminary tests
  • Total prostate specific antigen test
  • Complex prostate specific antigen test
  • Free prostate specific antigen test
• Confirmatory tests
  • Biopsy
  • Trans-rectal ultrasound
  • PCA3Test

Market, By Application

• Prostate cancer screening
• Prostate cancer monitoring

Market, By End Use

• Hospitals
• Diagnostic centers
• Specialty clinics
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE